Page last updated: 2024-11-06

n-acetylmuramic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N-acetylmuramic acid: RN given refers to D-Glucopyranose, (R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-acetyl-D-muramic acid : The pyranose form of N-acetylmuramic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5462244
CHEBI ID21615
CHEBI ID47965
SCHEMBL ID15504324
MeSH IDM0099267

Synonyms (21)

Synonym
(+)-n-acetylmuramic acid
n-acetyl-d-muramoate
n-acetylmuramic acid
murnac ,
n-acetylmuramate
C02713
n-acetyl-d-muramic acid
2-acetamido-3-o-[(1r)-1-carboxyethyl]-2-deoxy-d-glucopyranose
CHEBI:21615
muramic acid, n-acetyl-
AKOS015916519
SCHEMBL15504324
2-acetamido-3-o-[(r)-1-carboxyethyl]-2-deoxy-d-glucopyranose
2-acetamido-3-(r)-lactate-2-deoxy-d-glucopyranose
n-acetyl-muramic acid
c11h19no8
Q27109407
(2r)-2-(((3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-4-yl)oxy)propanoic acid
(2r)-2-(((3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-4-yl)oxy)propanoicacid
2245794-62-9
chebi:47965
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acetylmuramic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Events associated with phagocytolytic activity of PMN cells213
Immune System91482
Innate Immune System41475
Antimicrobial peptides3818
ROS and RNS production in phagocytes1237
Peptidoglycan cytoplasmic synthesis and recycling pathways834

Research

Studies (103)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (8.74)18.7374
1990's17 (16.50)18.2507
2000's23 (22.33)29.6817
2010's41 (39.81)24.3611
2020's13 (12.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (6.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other97 (93.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]